SCHEMBL4025554

SCHEMBL4025554

CN(C[C@]1(c2ccccc2)C[C@@H]1C=O)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 6/20 0.39
SLC6A3 Q01959 5/20 0.39
SLC6A4 P31645 5/20 0.39
OPRM1 P35372 3/20 0.38
OPRL1 P41146 3/20 0.38
OPRK1 P41145 1/20 0.36
CHRM2 P08172 3/20 0.35
CHRM4 P08173 3/20 0.35
CHRM5 P08912 3/20 0.35
CHRM1 P11229 3/20 0.35
CHRM3 P20309 3/20 0.35
CYP2D6 P10635 1/20 0.35
HTR2C P28335 1/20 0.35
MAOB P27338 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
CA12 O43570 1/20 0.34
CA9 Q16790 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4019257 1.00 SLC6A2 (0.39) SLC6A2SLC6A3SLC6A4OPRM1OPRL1
SCHEMBL4024571 1.00 SLC6A2 (0.39) SLC6A2SLC6A3SLC6A4OPRM1OPRL1
SCHEMBL4028181 1.00 SLC6A2 (0.39) SLC6A2SLC6A3SLC6A4OPRM1OPRL1
SCHEMBL13720416 0.85 SLC6A4 (0.36) SLC6A2SLC6A3SLC6A4OPRM1OPRL1
SCHEMBL13720163 0.85 SLC6A4 (0.36) SLC6A2SLC6A3SLC6A4OPRM1OPRL1
SCHEMBL13720388 0.85 SLC6A4 (0.36) SLC6A2SLC6A3SLC6A4OPRM1OPRL1
SCHEMBL4681356 0.85 SLC6A4 (0.36) SLC6A2SLC6A3SLC6A4OPRM1OPRL1
SCHEMBL13720136 0.85 SLC6A4 (0.36) SLC6A2SLC6A3SLC6A4OPRM1OPRL1
SCHEMBL6187298 0.80 SLC6A2 (0.34) SLC6A2SLC6A3SLC6A4CYP2D6HTR2C
SCHEMBL6170254 0.80 SLC6A2 (0.34) SLC6A2SLC6A3SLC6A4CYP2D6HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569579-B2 for inhibition of HIV replication and treatment of acquired immune deficiency syndrome SMITHKLINE BEECHAM CORPORATION (US) 2009-08-04 US disclosed
EP-1569934-B1 CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2008-01-23 EP disclosed
US-20060052408-A1 Cyclopropyl compounds as ccr5 antagonists SMITHKLINE BEECHAM CORPORATION 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052408-A1 Cyclopropyl compounds as ccr5 antagonists CCR5, CCR1, CCL5 SLC6A2 1961/4885SLC6A3 1853/4885SLC6A4 1697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.